Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

KEYTRUDA: metastatic esophageal cancer with PD-L1 stated without a specific alteration after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .

Broader topic: Esophageal Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    PD-L1
    alteration
    stated without a specific alteration
    status
    present
prior therapy
  1. class
    after one or more prior lines of systemic therapy for patients with tumors of squamous
    status
    required
derivation status
source-attested
derivation note
Scoped from the FDA approved indication for KEYTRUDA (product label). Only dimensions stated in that wording are part of this definition.
source wording
1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .

Study evidence for this setting

0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

Source relationships and population-mapping limitations
bindings
    mappings

      Download this complete draft source relationship record →

      Preserved source evidence · Not medical advice